NEW YORK – Companion diagnostics and next-generation sequencing are becoming more and more important for diagnostics companies, and NeoGenomics is no exception.
On recent earnings calls and in documents filed with the US Securities and Exchange Commission, NeoGenomics has touted upcoming developments in both companion diagnostics and next-generation sequencing areas.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
